{
    "medicine_id": "28c8255492553e059b36af7d7b6d9ef00cac4d93",
    "platform_id": "DB11630",
    "metadata": {
        "name": "Foscan 1 mg ml Injection solution",
        "composition": "1 mg ml Temoporfin",
        "clinical_particulars": {
            "therapeutic_indications": "For use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy surgery or systemic chemotherapy FDA Label",
            "contraindications": {
                "disease": "Mice and rats experienced swelling and darkening of exposed tissue at single dosages of 0 85 mg kg under normal lighting L1128 Systemic toxicity presented as reduced red blood cell and platelet counts and increased white blood cell counts and liver and spleen weights Skin inflammation pycnotic spermatocytes and increased extramedullary haematopoiesis in spleen and the lymph nodes was also observed Under low light conditions mild phototoxicity was observed only at high doses Severe phototoxicity has been seen in rats with repeated doses of up to 1 mg kg day under normal lighting L1128 This effect is less severe under low light conditions Two weeks of repeated doses of 0 5 0 6 mg kg day resulted in inflammation of the injection site and skin in rats At 0 3 mg kg day under low light in rats the only effect seen was an increase in white blood cell counts In beagle dogs recieving repeated doses of up to 3mg kg day under low light conditions reddening of the skin and injection site inflammation was seen L1128 Serious injection site damage was observed",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Temoporfin is a photosensitizing agent FDA Label It enters cancer cells and is activated via light to produce reactive species which destroy the cell",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Temoporfin"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Temoporfin"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Temoporfin"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Temoporfin"
                    },
                    {
                        "drugbank-id": "DB00707",
                        "description": "Temoporfin may increase the photosensitizing activities of Porfimer sodium"
                    },
                    {
                        "drugbank-id": "DB00460",
                        "description": "Temoporfin may increase the photosensitizing activities of Verteporfin"
                    },
                    {
                        "drugbank-id": "DB00755",
                        "description": "The risk or severity of adverse effects can be increased when Tretinoin is combined with Temoporfin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}